{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-081265","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.452992+00:00","generated_at":"2026-06-10T02:38:06.886580+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper Therapeutics receives FDA IND clearance for Phase 1b/2a study of briquilimab in chronic spontaneous urticaria","bullets":["FDA cleared IND for Phase 1b/2a repeat dose study of subcutaneous briquilimab in CSU patients.","First patient expected by end of 2023; early data from initial cohorts by mid-2024.","Separate CIndU proof-of-concept study to start Q1 2024 with initial data by year-end 2024.","Study enrolls ~40 patients across 6 cohorts; primary endpoints safety/tolerability, secondary efficacy/PK.","Targets CSU patients ineligible for or refractory to omalizumab, a high unmet need population."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-081265","json":"https://secwatch.observer/filing/0001213900-23-081265.json","markdown":"https://secwatch.observer/filing/0001213900-23-081265.md","text":"https://secwatch.observer/filing/0001213900-23-081265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081265/0001213900-23-081265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081265/ea186487-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:38:06.886580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}